FDA has approved a second biosimilar version of the widely used injection psoriasis drug Stelara, which will be known as Selarsdi. It’s slated to enter the market on or after Feb. 21, 2025, following a settlement with Johnson & Johnson, the manufacturer of Stelara. If Stelara’s biosimilars capture a large enough market share, they could impact the drug’s status as one of the 10 drugs initially selected for CMS’ inaugural drug price negotiation program. The biosimilar makers Alvotech and Teva...